Mark Page
Impact in
- Virology top 1%
- HIV Research and Treatment
- Infectious Diseases top 2%
- SARS-CoV-2 and COVID-19 Research
- Viral Infections and Outbreaks Research
- COVID-19 Clinical Research Studies
Papers in
- Virology 28
- HIV Research and Treatment 28
-
- Viral Infections and Outbreaks Research 20
- SARS-CoV-2 and COVID-19 Research 12
- Co-authors
- Robin Thorpe (35 shared papers)Giada Mattiuzzo (17 shared papers)Ivana Knežević (4 shared papers)Paul A. Kristiansen (2 shared papers)Valentina Bernasconi (2 shared papers)Karen W. Makar (2 shared papers)Stanley Alan Plotkin (1 shared paper)Peter M Dull (1 shared paper)
- Journals
- Vaccine (8 papers)Retrovirology (6 papers)The Lancet Microbe (5 papers)PLoS ONE (5 papers)npj Vaccines (4 papers)
- Partner nations
- United KingdomGermanyUnited States
In The Last Decade
Mark Page
107 papers receiving 1.9k citations
Mark Page's Hit Papers
Peers
Comparison fields: 5 of 124
- Virology 570
- Infectious Diseases 898
- Immunology 475
- Epidemiology 468
- Modeling and Simulation 49
Countries citing papers authored by Mark Page
This map shows the geographic impact of Mark Page's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Page with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Page more than expected).
Fields of papers citing papers by Mark Page
This network shows the impact of papers produced by Mark Page. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Page. The network helps show where Mark Page may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Page, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | WHO International Standard for anti-SARS-CoV-2 immunoglobulin Hit paper breakdown → | 2021 | 279 |
| 2 | 1990 | 154 | |
| 3 | 1993 | 131 | |
| 4 | 2021 | 104 | |
| 5 | 1989 | 72 | |
| 6 | 2018 | 70 | |
| 7 | 2002 | 56 | |
| 8 | 1994 | 51 | |
| 9 | 2015 | 51 | |
| 10 | 2006 | 43 | |
| 11 | 2010 | 38 | |
| 12 | 2012 | 35 | |
| 13 | 1992 | 32 | |
| 14 | 2008 | 31 | |
| 15 | 2017 | 30 | |
| 16 | 1990 | 28 | |
| 17 | 1999 | 27 | |
| 18 | 2008 | 27 | |
| 19 | 2021 | 27 | |
| 20 | 1983 | 26 |
About Mark Page
Mark Page is a scholar working on Virology, Infectious Diseases, Radiology, Nuclear Medicine and Imaging, Immunology and Epidemiology, having authored 115 papers that have together received 2.0k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (30 papers), HIV Research and Treatment (28 papers), Protein purification and stability (24 papers), Viral Infections and Outbreaks Research (20 papers), Glycosylation and Glycoproteins Research (15 papers), SARS-CoV-2 and COVID-19 Research (12 papers), Hepatitis B Virus Studies (11 papers) and Virology and Viral Diseases (10 papers). The work is most often cited by research in Virology (570 citations), Infectious Diseases (898 citations), Immunology (475 citations), Epidemiology (468 citations) and Modeling and Simulation (49 citations). Mark Page has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Robin Thorpe, Giada Mattiuzzo, Ivana Knežević, Paul A. Kristiansen, Valentina Bernasconi, Karen W. Makar, Stanley Alan Plotkin, Peter M Dull, Neil M. Almond and Andrew F. Rowley. Their work appears in journals such as Vaccine, Retrovirology, The Lancet Microbe, PLoS ONE and npj Vaccines.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.